Avidity Biosciences Inc
RNA
查看详细走势图
72.900USD
+0.080+0.11%
收盘 02/06, 16:00（美东）报价延迟15分钟
10.70B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.11%
5天
+0.45%
1月
+0.73%
6月
+53.41%
今年开始到现在
+1.07%
1年
+108.76%
查看详细走势图
TradingKey Avidity Biosciences Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Avidity Biosciences Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名56/159位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价72.62。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Avidity Biosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Avidity Biosciences Inc亮点
亮点风险
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
业绩高增长
公司营业收入稳步增长，连续3年增长18.14%
业绩增长期
公司处于发展阶段，最新年度总收入10.90M美元
利润高增长
公司净利润处于行业前列，最新年度总收入10.90M美元
估值低估
公司最新PE估值-17.38，处于3年历史低位
机构减仓
最新机构持股151.27M股，环比减少5.87%
HACAX持仓
明星投资者HACAX持仓，最新持仓市值8.53K
活跃度增加
近期活跃度增加，过去20天平均换手率0.87
分析师目标
根据
14
位分析师
持有
评级
72.615
目标均价
-0.14%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Avidity Biosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Avidity Biosciences Inc简介
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
公司代码RNA
公司Avidity Biosciences Inc
CEOBoyce (Sarah)
网址https://www.aviditybiosciences.com/
相关品种
